JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/01.qai.0000413723.17107.77
Abstract Index

    101—Understanding How HAART Works

    Robert F. Siliciano - Johns Hopkins University School of Medicine

    102—A Novel Innate Pathway for Antibody Diversification and Production

    Andrea Cerutti - Department of Medicine, Mount Sinai School of Medicine

    103—HIV-1 gp120 Interactions With the Gut Homing Receptor Integrin α4β7 on CD4+ T Cells

    J. Arthos - NIH/NIAID, Bethesda, MD

    104—New Treatment of Hepatitis C Virus Infection

    David L. Thomas - Johns Hopkins University School of Medicine

    105—New Antivirals and New Antiviral Strategies for HIV

    John G. Bartlett - Johns Hopkins University School of Medicine, Baltimore, MD

    106—Targeting CCR5 Density for Treatment and Prevention

    Robert Redfield - Institute of Human Virology

    107—Interleukin-7 As an Immune Reconstitution Agent in HIV-1 Infection: Ex Vivo and in Vivo Protective Effects on CD4+ T Cells

    Paolo Lusso - National Institute of Allergy and Infectious Diseases, National Institutes of Health

    108—Towards Coitally-Independent Microbicides: Studies with Vaginal Rings and Silicone-Based Gel Delivery Systems

    John P. Moore - Cornell University, Weill Medical College

    109—HIV-1 Transmission From Semen to the Female Genital Tract and its Prevention, as Seen in an ex vivo Tissue Model

    Leonid Margolis- Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health

    110—Hard Knocks: Communicating Science to the Public

    Paul Offit - The Children's Hospital of Philadelphia

    111—Interactions Between HIV Env and Germline Versions of bNAbs

    Leonidas Stamatatos - Seattle BioMed, Seattle, WA

    112—Diversity of Specificity and Function Among Human Antibodies to Transitional Epitopes Altered by CD4 Binding to the HIV-1 Env Glycoprotein

    G. K. Lewis - Institute of Human Virology, University of Maryland School of Medicine

    113—Immune Correlates of Infection Risk in the Thai Phase III ALVAC-HIV/AIDSVA-B/E Prime Boost Study

    Nelson L. Michael - Walter Reed Army Institute of Research, U.S. Military HIV Research Program

    114—Role of Vaccine-Induced V2 Antibodies in Protection from HIV Infection of Recipients in the RV144 Clinical Vaccine Trial

    Susan Zolla-Pazner - NYU School of Medicine and New York Veterans Affairs Medical Center

    115—DNA and Protein Vaccination via Electroporation Confers Protection Upon Mucosal Challenge with Heterologous SIVsmE660

    G.N. Pavlakis - Human Retrovirus Section, Vaccine Branch, CCR, NCI, Frederick

    116—Autologous and Heterologous Neutralizing Antibody Responses in HIV-1 Infection

    David Montefiori - Duke University Medical Center

    117—Ending the HIV/AIDS Pandemic: A Realistic Goal

    Anthony S. Fauci - National Institute of Allergy and Infectious Diseases, National Institutes of Health

    119—Deep Panning - High Resolution Profiling Antibody Specificities

    Jonathan M. Gershoni - Department of Cell Research and Immunology, Tel Aviv University

    120—Structural Immunology and Vaccine Development

    Peter D. Kwong - National Institute of Allergy and Infectious Diseases, National Institutes of Health

    121—Effect of Activating KIR Copy Number Variation on NK Cell Containment of SIV Replication in Rhesus Monkeys

    Norman L. Letvin - Beth Israel Deaconess Medical Center, Harvard Medical School

    122—Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys

    Dan H. Barouch - Beth Israel Deaconess Medical Center

    123—Vaccine-Elicited Antibodies Contribute to Protective Efficacy, Including Mucosal Antibodies, Correlated with Delayed SIV Acquisition

    Marjorie Robert-Guroff - NCI, Bethesda, MD

    124—GeoVax HIV/AIDS Vaccine Program, Preclinical and Clinical Studies

    Harriet L. Robinson - GeoVax Labs Inc.

    125—The Dynamics of Early HIV Infection and a Consequent New Approach to Vaccine Design

    James I Mullins - University of Washington

    126—Broadly Neutralizing HIV Abs: Gains and Losses in Translation

    G. J. Nabel - Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health

    127—Fighting AIDS Denialism

    Nicoli Nattrass - University of Cape Town

    128—Toward a Universal Influenza Virus Vaccine

    Peter Palese - Department of Microbiology Mount Sinai School of Medicine

    129—Live Attenuated Vaccine Induced Mucosal Antibodies and Early Events in the SIV-NHP Model of HIV-1 Transmission to Women

    Ashley T. Haase - University of Minnesota

    130—Neutralizing and Non-Neutralizing HIV-Specific Antibodies Hinder the Movement of Virus in Fresh Human Cervical Mucus

    Thomas J. Hope - Northwestern University Feinberg School of Medicine

    131—Characteristics of Transmitted Founder Viruses: Impact of Transmitting Partner Genetics

    E. Hunter - University of Alabama at Birmingham

    132—Antibodies and Fc Receptors: Their Potential Impact on HIV Infection

    Donald Forthal - University of California - Irvine

    134—HIV DNA Integration: Mechanism and Consequences

    Frederic D. Bushman - University of Pennsylvania School of Medicine

    135—Tetherin - Keeping Virions on a Leash

    Paul D. Bieniasz - HHMI, ADARC, The Rockefeller University

    136—A Roadmap Towards HIV Infection Cure

    Alain Lafeuillade - General Hospital

    137—Stem Cell Therapy for HIV Disease

    Irvin S. Y. Chen - UCLA AIDS Institute

    138—Mechanisms of Virus Clearance from the Nervous System

    Diane E. Griffin - Johns Hopkins Bloomberg School of Public Health

    139—Epitope Masking Mechanism Within the HIV-1 Env Trimer Analyzed by Functional Subunit Complementation

    E. A. Berger - Laboratory of Viral Diseases

    140—Antiviral Immune Responses, Chronic Immune Activation, and Pattern of Infected Cells in AIDS Pathogenesis: A Lesson from Non-Human Primate Models

    Guido Silvestri - Emory University School of Medicine

    141—The Role of T Memory Stem Cells: Pathogenesis and Vaccines

    Mario Roederer - ImmunoTechnology Section, VRC, NIAID, NIH

    142—Cause and Consequence of CD4-Negative T Cell Depletion During HIV Disease

    C. David Pauza - Institute of Human Virology, University of Maryland School of Medicine

    143—Pediatric HIV Infection: Forging a Path Towards Therapeutic Vaccination

    Paolo Rossi - University Department of Paediatrics (DPUO), Children Hospital

    144—The Cytosolic Exonuclease TREX1 Digests HIV Reverse Transcripts to Avoid Triggering an Antiviral Interferon Response in T Cells and Macrophages

    Judy Lieberman - Immune Disease Institute

    145—Pyroptosis and HIV-Induced CD4 T Cell Death

    Warner C. Greene - Gladstone Institute of Virology and Immunology, University of California

    146—Therapy Against HIV-1/AIDS: Past, Present, Future

    Samuel E. Broder - The Children's Hospital of Philadelphia

    147—Developing AIDS Associated Cancer Research in Africa

    Clement Adebamowo - Institute of Human Virology, Abuja, Nigeria

    148—Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Related Multicentric Castleman's Disease (MCD) and Inflammatory Cytokine Syndrome (KICS): Pathogenesis and Treatment

    Robert Yarchoan - National Cancer Institute

    149—Hepatitis C Virus (HCV)-Related Lymphoproliferative Disorders

    Anna Linda Zignego - Center for Systemic Manifestation of Hepatitis Viruses- University of Florence

    150—Update on Malignancies Among People with HIV/AIDS

    James Goedert - National Cancer Institute, Rockville

    151—Virally Associated Malignancies in the HIV Era

    Sam M. Mbulaiteye - Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute

    152—Can We Cure HTLV-I Associated Adult T Cell Leukemia Lymphoma?

    Ali Bazarbachi - American University of Beirut

    153—Transformation of Human Cells by HTLV-1 Tax

    Kuan-Teh Jeang - National Institute of Allergy and Infectious Diseases

    154—Retooling the Macaque Model to Evaluate the Relative Efficacy of HIV Vaccine Candidates

    Genoveffa Franchini - National Cancer Institute

    155—CD4+CD25+CD127low Regulatory T Cells: MicroRNA Signature and Effect of Valproate on microRNA and FOXP3 Expression Levels

    Bassam Badran - Laboratory of Experimental Hematology, Institut Jules Bordet, Universite' Libre de Bruxelles, Bruxelles, Belgium

    156—What Happens When Your Viral Flora Gives You Cancer?

    Patrick Moore - Cancer Virology Program, University of Pittsburgh Cancer Institute

    157—Strategies for Anti-Cancer Immunotherapy Using Vaccines and Blockade of Negative Regulation

    Jay A. Berzofsky - Vaccine Branch, CCR, NCI, NIH

    © 2012 Lippincott Williams & Wilkins, Inc.